## In the Claims:

A complete listing of the claims with proper claim identifiers is set forth below.

Claims 1-3 (Cancelled).

4. (Currently Amended) A gene therapy vector, comprising:

a first polynucleotide encoding a gene for B subunit of a cytolethal distending toxin; and

<u>a second polynucleotide encoding an antisense oligonuoleotide that</u> <u>inhibits expression of a sense oligonucleotide encoding a DNA repair protein;</u>

wherein the first and second polynucleotides are operably linked to an inducible promoter;

wherein the inducible promoter is a heat shock promoter;

wherein the inducible promoter is a segment of a heat shock promoter that is strictly inducible by heat shock; and

The gene therapy vector of claim 3, wherein the inducible promoter has a nucleotide sequence of SEQ ID 7.

Claims 5 and 6 (Cancelled).

7. (Currently Amended) The gene therapy vector of claim 4, wherein the gene is *E. coli* cdtB; and

The gene therapy vector of claim 6, wherein the gene has a nucleotide sequence of SEQ ID 5.

Claims 8 and 9 (Cancelled).

Application Serial No. <u>10/764,316</u> Client/Matter No. <u>10546-109</u>

10. (Currently Amended) The gene therapy vector of claim 4, wherein the second polynucleotide encodes an antisense oligonucleotide that inhibits expression of a sense oligonucleotide encoding a protein involved in the non-homologous end-joining DNA repair mechanism;

wherein the protein is ku70; and

The gene therapy vector of claim 9, wherein the second polynucleotide is complimentary to nucleotide sequence SEQ ID 6.

Claims 11 - 32 (Cancelled).